Key result
Torsemide and furosemide offer equivalent volume control and clinical outcomes in heart failure, with no major differences in hospitalization or mortality rates.
Why the study?
Pharmacokinetic and mechanistic differences between torsemide and furosemide prompted questions regarding whether torsemide offers superior clinical outcomes.
Does torsemide improve clinical outcomes compared to furosemide in patients with heart failure and chronic kidney disease?
Does torsemide improve clinical outcomes compared to furosemide in patients with heart failure and chronic kidney disease?
Despite pharmacokinetic differences, torsemide and furosemide provide equivalent volume control and clinical outcomes in patients with heart failure.
Torsemide's pharmacokinetic advantages over furosemide leave open any superiority in HF outcomes; randomized trials needed before practice change.
Furosemide and torsemide are both loop diuretics that have widespread use to manage fluid excess in heart failure (HF), chronic kidney disease, and secondary conditions. These drugs work through inhibition of the Na+-K+-2Cl- cotransporter in the Henle's loop, thus bringing about diuresis and symptomatic relief. Torsemide is different from furosemide pharmacokinetically and mechanism-wise-with higher oral bioavailability, longer half-life, and potential anti-aldosterone effect-and these differences have prompted studies of whether it offers superior clinical outcomes. Herein, furosemide and torsemide are contrasted in mechanisms of action, clinical application, efficacy (diuretic effectiveness and results in HF and chronic kidney disease), safety profile, and price. Current evidence from meta-analyses and clinical trials indicates that both medications offer equivalent volume control and clinical outcomes in HF, with no major differences in hospitalization or mortality rates.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2025) conducted a review in Heart failure and chronic kidney disease. Torsemide vs. Furosemide was evaluated on Volume control, hospitalization, and mortality rates. Torsemide and furosemide offer equivalent volume control and clinical outcomes in heart failure, with no major differences in hospitalization or mortality rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: